Similar observations have been made in the case of another chimeric anti-CD37 antibody-BI 836826, which has demonstrated increased efficacy against CLL cells in vitro when combined with PI3K inhibitor idelalisib [50]. This evidence concerns the gene CD37 and B-cell chronic lymphocytic leukemia.